Zebrafish xenograft breast cancer models for high-throughput drug response screening

Rebecca Schmitz, Alex J. Walsh, Kelsey Tweed, Steve Trier, Anna Huttenlocher, Melissa C. Skala

Research output: Chapter in Book/Report/Conference proceedingConference contribution


The heterogeneity and dynamic nature of cancerous tumors, such as those seen in breast cancer, pose a unique challenge in determining treatment regimens. The use of zebrafish as an in vivo model of breast cancer provides a high-throughput model with the potential to screen for efficacious drugs on a patient-by-patient basis. In this study, we use two-photon microscopy to measure metabolic changes in zebrafish with xenografted breast cancer tumors before, during, and after treatment with the anti-cancer drug paclitaxel. We use this metabolic imaging data to evaluate the zebrafish as a robust in vivo model of breast cancer. Preliminary results suggest the xenograft tumors respond to treatment with paclitaxel at 48 hours post treatment, as demonstrated by significant changes in NAD(P)H fluorescence lifetimes.

Original languageEnglish (US)
Title of host publicationBiophysics, Biology and Biophotonics IV
Subtitle of host publicationThe Crossroads
EditorsAdam Wax, Vadim Backman
ISBN (Electronic)9781510624184
StatePublished - 2019
EventBiophysics, Biology and Biophotonics IV 2019: The Crossroads - San Francisco, United States
Duration: Feb 2 2019 → …

Publication series

NameProgress in Biomedical Optics and Imaging - Proceedings of SPIE
ISSN (Print)1605-7422


ConferenceBiophysics, Biology and Biophotonics IV 2019: The Crossroads
Country/TerritoryUnited States
CitySan Francisco
Period2/2/19 → …


  • FAD
  • Multiphoton microscopy
  • NAD(P)H
  • breast cancer
  • drug screen-ing
  • uorescence lifetime imaging

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Atomic and Molecular Physics, and Optics
  • Biomaterials
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Zebrafish xenograft breast cancer models for high-throughput drug response screening'. Together they form a unique fingerprint.

Cite this